Welcome to the e-CCO Library!

P530: Azathioprine in the maintenance of steroid-free remission in inflammatory bowel disease patients: efficacy and safety in five years of follow-up
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Cassieri C.*1, Pica R.1, Avallone E.V.1, Brandimarte G.2, Zippi M.1, Crispino P.1, De Nitto D.1, Lecca G.2, Corrado C.1, Vernia P.1, Paoluzi P.1, Corazziari E.S.1

Created: Wednesday, 20 February 2019, 10:36 AM
P530: Proactive therapeutic drug monitoring of anti-TNF agents is associated with higher mucosal healing rates in Crohn's disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Brinar, M.(1);Sabic , M.(1);Turk , N.(1);Grgic, D.(1);Domislovic, V.(1);Cukovic Cavka, S.(1);Kozmar, A.(2);Krznaric, Z.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P530: Psychosexual dysfunction in Greek patients with inflammatory bowel disease in remission
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Dimitriadis, D. Xanthis, P. Paschos, A. Katsoula, N. Grammatikos, A. Tsimperidis, K. Soufleris, O. Giouleme*

Created: Thursday, 21 February 2019, 9:14 AM
P530: The Burden on Cohabitants of Patients with Inflammatory Bowel Disease: A Cross-Sectional Study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: López-Vico, M.(1)*;Sánchez-Capilla, A.D.(1);Martín-Rodríguez, M.D.M.(1);Cabello-Tapia, M.J.(1);Redondo-Cerezo, E.(1);
Created: Friday, 14 July 2023, 11:05 AM
P530: Ultra-proactive therapeutic drug monitoring incorporating infliximab point-of-care testing with ad hoc dose adjustment reduces C-reactive protein levels in patients with IBD during infliximab maintenance treatment
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Bossuyt*1,2, E. Hoefkens2, I. Geerts3, F. Verbiest4, E. Vermeulen3, A. Van Olmen2, L. Pouillon2

Created: Friday, 22 February 2019, 9:41 AM
P530: Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease - a systematic review with meta-analysis
Year: 2022
Source: ECCO'22
Authors: Attauabi, M.(1,2,3);Madsen, G.R.(1,2);Bendtsen, F.(1,2);Seidelin, J.B.(3);Burisch, J.(2);
Created: Friday, 11 February 2022, 3:56 PM
P531 A retrospective audit of the inflammatory bowel disease specialist nurse-led telephone advice service
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Watters, W. Lloyd, M. Porteous, M. Mohamed, S. Kari, E. Nelson, R. Saravanan

Created: Thursday, 30 January 2020, 10:12 AM
P531: A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kantasiripitak, W.(1);WIcha, S.G.(2);Thomas, D.(1);Hoffman , I.(3);Ferrante , M.(4,5);Vermeire , S.(4,5);van Hoeve , K.(3);Dreesen, E.(1,6)*;
Created: Friday, 14 July 2023, 11:05 AM
P531: Discontinuation of corticosteroids among Crohn's disease patients treated with vedolizumab in the United States
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Patel H.*1, Chastek B.2, Null K.D.3, Demuth D.4

Created: Wednesday, 20 February 2019, 10:36 AM
P531: Efficacy of tofacitinib maintenance therapy for ulcerative colitis in remitting patients vs. patients with clinical response after 8 weeks of induction treatment
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Reinisch*1, M. T. Osterman2, G. Doherty3, A. Marren4, D. A. Woodworth4, N. Lawendy4, K. Kwok5, E. Maller4, C. Su4

Created: Friday, 22 February 2019, 9:41 AM
P531: SARS-CoV-2 infection in Elderly patients with Inflammatory Bowel Disease with or without immunosuppressants during the first year of the pandemic. An observational, descriptive, cohort study.
Year: 2021
Source: ECCO'21 Virtual
Authors: Calafat Sard, M.(1,2);González-Muñoza: , C.(3); Fortuny, M.(1);Roig, C.(3);Calm, A.(1);Mombiela, A.(3);Teller-Martin, M.(3);Cañete:, F.(1,2);Bertoletti, F.(3);González-González, L.(1);Gordillo, J.(3);Mañosa, M.(1,2);Garcia-Planella , E.(3);Domènech, E.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P531: Stringent screening strategy significantly reduces reactivation rate of Tuberculosis in Patients with Inflammatory Bowel Disease on anti-TNF therapy in a TB endemic region
Year: 2022
Source: ECCO'22
Authors: Kumar, P.(1);Vuyyuru, S.K.(1);Kante, B.(1);Sahu, P.(1);Goyal, S.(1);Madhu, D.(1);Jain, S.(1);Ranjan, M.K.(1);Mundhra, S.(1);Golla, R.(1);Singh, M.(1);Virmani, S.(1);Gupta, A.(1);Yadav, N.(1);Kalaivani, M.(1);Sharma , R.(1);Das, P.(1);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
Created: Friday, 11 February 2022, 3:56 PM
P531: Tuberculin skin test conversion rate in inflammatory bowel disease patients receiving anti-TNFα agents
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Fragaki*, G. Paspatis, K. Karmiris

Created: Thursday, 21 February 2019, 9:14 AM
P532 Measuring endoscopic activity in patients treated with vedolizumab for ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. EMONT1, C. Gay2, A.L. Parmentier3, S. Koch4, S. Ambregna5, G. Claudé5, P. Sage5, P. Zhong4, C. Briot5, L. Vuitton4

Created: Thursday, 30 January 2020, 10:12 AM
P532: 1-Year Clinical Outcome of Subcutaneous Infliximab compared with Intravenous Infliximab in Patients with Inflammatory Bowel Disease During Maintenance Therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Song, J.H.(1);Hong, S.N.(2)*;Kim, E.R.(3);Kim, J.E.(3);Chang, D.K.(3);Kim, Y.H.(3);
Created: Friday, 14 July 2023, 11:05 AM
P532: Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients – one-year clinical follow-up
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kolar M.*1, Duricova D.1,2, Bortlik M.1,3, Hruba V.1, Machkova N.1, Mitrova K.1,4, Lukas M.1, Malickova K.5, Lukas M.1,5

Created: Wednesday, 20 February 2019, 10:36 AM
P532: Delay of maintenance infliximab increases the risk of relapse in Crohn’s disease during the COVID-19 pandemic
Year: 2021
Source: ECCO'21 Virtual
Authors: Guo, H.(1);Tang, J.(1);Huang, Z.(1);Li, B.(1);Yang, Q.(1);Chao, K.(1);Gao, X.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P532: Efficacy of combination therapy with cyclosporin and vedolizumab in inflammatory bowel diseases refractory to anti-TNF agents
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Rutka*, K. Szántó, R. Bor, A. Bálint, A. Fábián, A. Milassin, Z. Szepes, K. Farkas, T. Molnar

Created: Thursday, 21 February 2019, 9:14 AM
P532: Proactive therapeutic drug monitoring improves clinical outcomes in patients with inadequate post-induction infliximab trough levels
Year: 2022
Source: ECCO'22
Authors: Botto, I.(1);Coelho Rodrigues, I.(1);Serrazina, J.(1);Fernandes, S.(1);Bernardo, S.(1);Gonçalves, A.R.(1);Moura Santos, P.(1);Valente, A.(1);Correia, L.(1);Tato Marinho, R.(1);
Created: Friday, 11 February 2022, 3:56 PM
P532: Safety and efficacy of endoscopic dilation of small bowel Crohn’s disease strictures by balloon-assisted enteroscopy: pooled analysis of individual data from 210 patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Bettenworth*1, A. Bokemeyer1, L. Kou2, R. Lopez2, B. P. Halloran3, M. Reeson3, S. Hosomi4, M. Kishi5, F. Hirai5, N. Ohmiya6, F. Rieder7,8

Created: Friday, 22 February 2019, 9:41 AM